Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

Clinical Infectious Diseases

Volumn 32, Issue 3, 2001, Pages 492-497

  Bica, Ioana ^a   McGovern, Barbara ^a,b,c   Dhar, Rakesh ^c   Stone, David ^a,b,c   McGowan, Katherine ^b,c,d   Scheib, Rochelle ^b,d   Snydman, David R ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Division of Infectious Diseases   (United States)

^d Lemuel Shattuck Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS C ANTIBODY; VIRUS RNA;

ADULT; ARTICLE; COMORBIDITY; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FAILURE; LIVER TOXICITY; LYMPHOCYTE COUNT; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL;

ADULT; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COMORBIDITY; FEMALE; HEPATITIS C; HIV INFECTIONS; HIV SEROPOSITIVITY; HOSPITALIZATION; HUMANS; LIVER FAILURE; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD;

EID: 0035112776     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/318501     Document Type: Article

References (32)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Hepatitis C virus infection in patients infected with human immunodeficiency virus
3. Prevalence of antibody to hepatitis C virus (HCV) in HIV-1-infected patients (nice SEROCO cohort)
4. Correlates of hepatitis C virus infections among injection drug users
5. Natural history of hepatitis C infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus
6. High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal trans-aminase levels
7. Natural history of hepatitis C
8. The natural history of community-acquired hepatitis C in the United States
9. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection
10. HCV RNA levels and HIV infection: Evidence for a viral interaction in haemophilic patients
11. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
12. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis
13. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV
14. The progression of HCV-associated liver disease in a cohort of haemophilic patients
15. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C
16. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users
17. Natural history of liver fibrosis progression in patients with chronic hepatitis C
18. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease
19. Hepatotoxicity after introduction of highly active antiretroviral therapy
20. Antituberculosis drug-induced hepatotoxicity: The role of hepatitis C virus and the human immunodeficiency virus
21. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy
22. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy
23. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
24. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
25. Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses
26. HIV-associated bacteremia: How it has changed in the highly active antiretroviral therapy (HAART) era
27. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: US Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA)
28. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users
29. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals
30. Interferon or interferon plus ribavirin for the treatment of hepatitis C virus infection among HIV-infected persons